Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of Neoadjuvant Erlotinib Plus Chemotherapy for Treatment of ER Negative, PgR Negative and HER-2 Negative Primary Breast Cancer.

Next Previous
X
Search
Trial Profile

Phase II Trial of Neoadjuvant Erlotinib Plus Chemotherapy for Treatment of ER Negative, PgR Negative and HER-2 Negative Primary Breast Cancer.

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erlotinib (Primary) ; Carboplatin; Docetaxel
  • Indications Adenocarcinoma; Breast cancer; Triple negative breast cancer
  • Focus Biomarker; Therapeutic Use

    • Most Recent Events

    • 18 Jan 2017 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017.
    • 31 Mar 2015 Planned End Date changed from 1 Mar 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov.
    • 05 Nov 2014 According to NCT record, planned End Date changed from 1 Dec 2014 to 1 Mar 2015.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top